

Personalised nutritional advice to aid weight loss

| | | |
|--|--|---|
| Submission date 19/10/2020 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol |
| Registration date 03/12/2020 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results |
| Last Edited 04/06/2025 | Condition category Nutritional, Metabolic, Endocrine | <input type="checkbox"/> Individual participant data |

Plain English summary of protocol

Background and study aims

Being obese is known to increase the chance of developing several health problems, including heart disease, type 2 diabetes, fatty liver disease, and some cancers. It results from the interactions of different factors, including genes, metabolism, behaviour, and environment. The latter factors include people's eating habits and how much exercise they do. However, both gaining and losing weight are complex because it is not known how the different factors interact.

This study aims to improve the health of obese people by developing personalized eating plans. In order to assess and characterize the patient's health status before and after dietary intervention, the project will measure various metabolic biomarkers. The aim of the study is to compare the effects of personalized dietary advice based on Preventomics software with general dietary recommendations on weight loss and improvement in metabolic health status.

Who can participate?

Healthy volunteers aged 18 to 65 years old with a BMI between 25-40 kg/m² with abdominal obesity.

What does the study involve?

Volunteers will be allocated in one of three groups: a control group, in which volunteers will receive general advice from a dietitian about how to improve their diet; a personalised nutrition group, in which participants will use MetaDieta app and the PREVENTOMICS' app; and the personalised plan group, in which, in addition to a personalised diet through the use MetaDieta and PREVENTOMICS' app, will also receive prompts to help change food and lifestyle choices. The intervention will last 4 months. Before and after the intervention, each participant will have blood, urine, saliva, and faeces samples taken for laboratory tests.

What are the possible benefits and risks of participating?

Participants may benefit from losing weight and receiving laboratory test results as well as scientific advice on how to improve diet and lifestyle. Dietary intervention is unlikely to lead to undesirable effects and complications. The only side effects of the test may result from venous blood collection, such as bruising and feeling weak.

Where is the study run from?
Jagiellonian University Medical College (Poland)

When is the study starting and how long is it expected to run for?
From September 2018 to April 2022

Who is funding the study?
The European Union's Horizon 2020 research and innovation programme (Belgium)

Who is the main contact?
Prof. Malgorzata Malczewska-Malec
m.malczewska-malec@uj.edu.pl

Study website
<https://preventomics.eu/study-personalised-nutritional-advice-weight-loss/>

Contact information

Type(s)
Scientific

Contact name
Prof Małgorzata Malczewska-Malec

ORCID ID
<https://orcid.org/0000-0002-3522-0711>

Contact details
Jagiellonian University Medical College
Department of Clinical Biochemistry
15A Kopernika Street
Kraków
Poland
31-501
+48 12 4214006
m.malczewska-malec@uj.edu.pl

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
Z/H20/00030

Study information

Scientific Title

The effect of personalized nutritional advice based on weight loss and health status of subjects with abdominal obesity: empowering consumers to prevent diet-related diseases

Study objectives

Personalized dietary advice based on omics science and Preventomics software is more effective at reducing weight and improving metabolic health status than general dietary recommendations in people with abdominal obesity.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 28/03/2019, Bioethics Committee of the Jagiellonian University (ul. Grzegórzecka 20, 31-531 Kraków, Poland; +48 12 433 27 39; kbet@cm-uj.krakow.pl), ref: 1072.6120.85.2019

Study design

Single-centre interventional single-blinded randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

GP practice

Study type(s)

Prevention

Participant information sheet

See study outputs table

Health condition(s) or problem(s) studied

Abdominal obesity

Interventions

Randomisation will take place once anthropometry is completed using an independent online computerized randomisation system by a member of the study team. Randomisation will be conducted at the level of the individual and will be stratified by sex, age, and waist circumference. Volunteers will be randomly allocated to one of the three groups:

1. Control group, in which volunteers will receive general advice from a dietitian about how to improve their diet
2. Personalised nutrition group, in which participants will use the PREVENTOMICS' mobile application alongside a dietitian to receive a personalised diet plan through MetaDieta mobile application
3. Personalised plan group, in which, in addition to advice from the dietitian and a personalised

diet through the use MetaDieta app and PREVENTOMICS' app, will also receive prompts to help change food and lifestyle choices

Each intervention will last for 4 months. At the start and at the end of the intervention, subjects will visit GP for health status screening, anthropometric measurements, and blood, urine, saliva, and faeces sample collection. In the collected material, analyses of genome, metabolome, and microbiome will be performed.

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Not provided at time of registration

Primary outcome measure

1. Waist circumference will be measured at baseline and 4 months

Secondary outcome measures

1. Classic clinical biomarkers measured using Enzyme-Linked Immunosorbent Assay (ELISA) at baseline and 4 months
2. Metabolomics biomarkers measured using Nuclear Magnetic Resonance (NMR) and Liquid Chromatography-Mass Spectrometry (LC/MS) at baseline and 4 months
3. Food intake biomarkers measured using Liquid Chromatography-Ion Mobility Spectrometry-Quadrupole Time of Flight Mass Spectrometry (LC-IMS-QToF MS) at baseline and 4 months
4. Microbiome analysis in faeces using Next Generation Sequencing (NCS) at baseline and 4 months

Overall study start date

13/09/2018

Completion date

30/04/2022

Eligibility**Key inclusion criteria**

1. Aged between 18-65 years
2. Waist circumference >94 cm for men or >80 cm for women
3. BMI between 25-40 in kg/m²
4. Provided written informed consent

Participant type(s)

Healthy volunteer

Age group

Adult

Lower age limit

18 Years

Upper age limit

65 Years

Sex

Both

Target number of participants

264

Total final enrolment

265

Key exclusion criteria

1. Diabetes
2. Severe hyperlipidemia
3. Other endocrine and metabolic diseases
4. Chronic inflammatory states
5. Diseases of the digestive or respiratory systems
6. Chronic kidney disease
7. Cardiovascular disease
8. Alcohol addiction
9. Pregnancy or lactation

Date of first enrolment

01/11/2020

Date of final enrolment

31/08/2021

Locations**Countries of recruitment**

Poland

Study participating centre

Jagiellonian University Medical College

Department of Clinical Biochemistry

Kopernika 15A

Kraków

Poland

31-501

Sponsor information

Organisation

Jagiellonian University

Sponsor details

Jagiellonian University Medical College

ul. Św. Anny 12

Krakow

Poland

30-006

+48 12 37 04 341

katarzyna.gubernat@uj.edu.pl

Sponsor type

University/education

Website

<https://cm-uj.krakow.pl/index.php/en/index>

ROR

<https://ror.org/03bqmcz70>

Funder(s)**Funder type**

Government

Funder Name

Horizon 2020 Framework Programme

Alternative Name(s)

EU Framework Programme for Research and Innovation H2020, Horizon 2020, Rahmenprogramm Horizont 2020, Programa Marco Horizonte 2020, Programme-cadre Horizon 2020, Programma quadro Orizzonte 2020, Program ramowy Horyzont 2020, Horizont 2020, Horizonte 2020, Orizzonte 2020, Horyzont 2020, Horizon 2020 Framework Programme (H2020), H2020

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location**Results and Publications**

Publication and dissemination plan

Planned publications in high-impact peer-reviewed journals.

Intention to publish date

31/12/2022

Individual participant data (IPD) sharing plan

All the data is stored in GDPR-compliant servers at EURECAT (leading Project partner in Barcelona) and it is only available to consortium members in a restrictive mode. It is planned to create a common database with the data from the different partners.

IPD sharing plan summary

Stored in non-publicly available repository

Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|--------------------|--------------|------------|----------------|-----------------|
| Participant information sheet | version v1.0 | 13/01/2020 | 03/12/2020 | No | Yes |
| Protocol file | | | 28/09/2022 | No | No |
| Basic results | | | 19/06/2023 | No | No |
| Other publications | Cost-effectiveness | 01/06/2025 | 04/06/2025 | Yes | No |